<DOC>
	<DOC>NCT00774072</DOC>
	<brief_summary>The purpose of this study is to determine whether the nasal inhalation of GernebcinÂ® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.</brief_summary>
	<brief_title>Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>subject has a confirmed diagnosis of cystic fibrosis detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of the lung (from day 28) informed consent of the patients or parents subject is older than 7 years subject is able to comply with the inhalation procedures and nasal lavage procedures scheduled in the protocol women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol subject has a critical condition defined as: FEV1 &lt; 30% and / or SaO2 &lt; 93% without O2substitution; need of O2substitution subject had an ENT surgery within 3 months prior to study subject shows signs of nasal bleeding subject has an ear drum perforation subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy against pseudomonas aerug. subject is unlikely to comply with the procedures scheduled in the protocol subject has a known allergic reaction to the medication subject is pregnant or breastfeeding subject participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study. systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the inclusion and during the study if serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to withdraw the participation in the study. progressed renal insufficiency severe damage of the N. acusticus dizziness (potential damage of. N. vestibularis)</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways</keyword>
</DOC>